Rite Aid reaches $410M settlement with DOJ in opioid false claims case
By 
Adrianne Appel2024-07-11T14:40:00
Rite Aid agreed to pay $7.5 million and allow the Department of Justice (DOJ) to access nearly $402 million from the company’s forthcoming bankruptcy case to settle allegations it helped fuel the nation’s opioid epidemic.
The DOJ case, brought on behalf of the Drug Enforcement Administration, the Department of Health and Human Services, and the Defense Health Agency, is just one of many local, state, and federal suits against pharmacies, opioid manufacturers, and others alleged to have spurred opioid addiction nationwide.
The case resolves claims brought under the qui tam provisions of the False Claims Act by three former Rite Aid pharmacy employees, Andrew White, Mark Rosenberg, and Ann Wegelin, the DOJ announced Wednesday in a press release. They will receive 17 percent of the DOJ’s recovery.
Related articles
-
News BriefMcKinsey & Co. to pay $650M, improve compliance over opioid advice to Purdue Pharma
McKinsey & Co. will pay $650 million in penalties to the U.S. Department of Justice (DOJ) to settle charges that it advised Purdue Pharma on how to “turbocharge” the sale of Oxycontin in the middle of the U.S. opioid crisis.
-
News BriefDOJ intervenes in suit alleging Rite Aid helped fuel opioid crisis
The Department of Justice announced its intervention in a lawsuit alleging retail pharmacy chain Rite Aid filled hundreds of thousands of prescriptions for medically unnecessary oxycodone and other opioids in violation of multiple federal laws.
-
ArticleWalmart to pay $3.1B in nationwide opioid settlement
Walmart announced it agreed to a $3.1 billion nationwide settlement designed to resolve all the potential state lawsuits it faces for its alleged role in fueling the opioid epidemic.
More from Regulatory Enforcement
-
News BriefCFPB ends probe into Meta’s financial advertising practices
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
-
News BriefTexas sues Johnson & Johnson, Kenvue over alleged misleading marketing of Tylenol
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.
-
News BriefCFPB scraps bad-actor registry, citing cost-benefit issues
The Consumer Financial Protection Bureau shut down a registry of non-bank financial firms that broke consumer laws. The agency cites the costs being ”not justified by the speculative and unquantified benefits to consumers.”